| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| N S Gunasekara, S Noble, P Benfiel. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs. vol 55. issue 1. 1998-03-05. PMID:9463792. |
paroxetine is a potent and selective inhibitor of the neuronal reuptake of serotonin (5-hydroxytryptamine; 5-ht), which was previously reviewed as an antidepressant in drugs in 1991. |
1998-03-05 |
2023-08-12 |
Not clear |
| N S Gunasekara, S Noble, P Benfiel. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs. vol 55. issue 1. 1998-03-05. PMID:9463792. |
in short term clinical trials in patients with depression, paroxetine produced clinical improvements that were significantly greater than those with placebo and similar to those achieved with other agents including tricyclic antidepressants (tcas), maprotiline, nefazodone and the selective serotonin reuptake inhibitors (ssris) fluoxetine, fluvoxamine and sertraline. |
1998-03-05 |
2023-08-12 |
Not clear |
| A Ramaiya, J H Johnson, H T Karne. Evaluation of the neuropharmacodynamics of paroxetine in vivo utilizing microdialysis. Journal of pharmaceutical sciences. vol 86. issue 12. 1998-02-26. PMID:9423168. |
the effect of paroxetine, a selective serotonin reuptake inhibitor used in the treatment of depression, on extracellular serotonin levels was evaluated in freely moving conscious rats. |
1998-02-26 |
2023-08-12 |
rat |
| A Ramaiya, J H Johnson, H T Karne. Evaluation of the neuropharmacodynamics of paroxetine in vivo utilizing microdialysis. Journal of pharmaceutical sciences. vol 86. issue 12. 1998-02-26. PMID:9423168. |
microdialysis, a powerful in vivo technique to monitor the extracellular levels of neurotransmitters, was used to monitor the baseline changes in the levels of serotonin in rat brain anterior lateral striatum post paroxetine administration, which is a measure of the neuropharmacodynamic effect of the drug. |
1998-02-26 |
2023-08-12 |
rat |
| A Ramaiya, J H Johnson, H T Karne. Evaluation of the neuropharmacodynamics of paroxetine in vivo utilizing microdialysis. Journal of pharmaceutical sciences. vol 86. issue 12. 1998-02-26. PMID:9423168. |
paroxetine caused a statistically significant increase in the extracellular levels of serotonin in the anterior lateral striatum sampled by microdialysis. |
1998-02-26 |
2023-08-12 |
rat |
| T W Seale, K Avor, S Singh, N Hall, H M Chan, G P Basmadjia. 2'-Substitution of cocaine selectively enhances dopamine and norepinephrine transporter binding. Neuroreport. vol 8. issue 16. 1998-02-26. PMID:9427328. |
we synthesized 2'-oh-, 2'-f- and 2'-acetoxy-cocaines and compared their binding potencies for rat dopamine, norepinephrine and 5-hydroxytryptamine transporters to cocaine, 3'-oh-, 4'-oh-, 2'-oh,4'-i-cocaine derivatives, and to the transporter selective ligands win 35,428, nisoxetine and paroxetine. |
1998-02-26 |
2023-08-12 |
rat |
| P J Cowen, P A Sargen. Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. Journal of psychopharmacology (Oxford, England). vol 11. issue 4. 1998-02-25. PMID:9443523. |
we studied the effect of the selective serotonin reuptake inhibitor (ssri), paroxetine, on basal plasma prolactin concentrations in 11 healthy subjects. |
1998-02-25 |
2023-08-12 |
human |
| P S Masand, S Gupt. Dexfenfluramine for weight gain secondary to psychotropics. Depression and anxiety. vol 6. issue 3. 1998-02-24. PMID:9442986. |
none of the patients had any evidence of primary pulmonary hypertension or serotonin syndrome, despite being on serotonergic agents such as fluoxetine, paroxetine, and sertraline. |
1998-02-24 |
2023-08-12 |
Not clear |
| D E Martin, B D Zussman, D E Everitt, L J Benincosa, R C Etheredge, D K Jorkask. Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men. Journal of clinical psychopharmacology. vol 17. issue 6. 1998-02-06. PMID:9408807. |
in light of recent reports that the selective serotonin reuptake inhibitor antidepressants may be weak cyp3a4 inhibitors, this study was designed to investigate the effects of paroxetine on the pharmacodynamic and pharmacokinetic profile of terfenadine. |
1998-02-06 |
2023-08-12 |
human |
| A L Weiner, F F Tilden, C A McKa. Serotonin syndrome: case report and review of the literature. Connecticut medicine. vol 61. issue 11. 1998-01-30. PMID:9419960. |
she was already being treated for depression with paroxetine (paxil), a selective serotonin reuptake inhibitor. |
1998-01-30 |
2023-08-12 |
Not clear |
| S Asano, T Matsuda, Y Nakasu, S Maeda, H Nogi, A Bab. Inhibition by nitric oxide of the uptake of [3H]serotonin into rat brain synaptosomes. Japanese journal of pharmacology. vol 75. issue 2. 1998-01-29. PMID:9414026. |
no-cys did not affect the specific binding of [3h]paroxetine, a ligand that binds to the 5-ht transporter, in membranes. |
1998-01-29 |
2023-08-12 |
rat |
| H Koponen, U Lepola, E Leinonen, R Jokinen, J Penttinen, J Turtone. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta psychiatrica Scandinavica. vol 96. issue 5. 1998-01-16. PMID:9395151. |
previous reports suggest that the disorder may be treated with the tricyclic antidepressant clomipramine, and also with the more recently introduced selective serotonin reuptake inhibitors (ssris), such as fluoxetine, fluvoxamine, sertraline and paroxetine. |
1998-01-16 |
2023-08-12 |
Not clear |
| S K Yeghiayan, S L Andersen, R J Baldessarin. Lack of effect of chronic clorgyline or selegiline on dopamine and serotonin transporters in rat caudate-putamen or nucleus accumbens septi. Neuroscience letters. vol 236. issue 3. 1998-01-12. PMID:9406758. |
nevertheless, no change in binding of [3h]gbr-12935 to the dopamine transporter or of [3h]paroxetine to the serotonin transporter in caudate-putamen or nucleus accumbens septi was found with quantitative autoradiography. |
1998-01-12 |
2023-08-12 |
rat |
| J M Gorma. The use of newer antidepressants for panic disorder. The Journal of clinical psychiatry. vol 58 Suppl 14. 1998-01-08. PMID:9418747. |
data from research trials as well as clinical experience are accumulating to indicate that the serotonin selective reuptake inhibitors (ssris)--fluoxetine, fluvoxamine, paroxetine, and sertraline--and perhaps venlafaxine, which inhibits both serotonergic and noradrenergic reuptake, are useful antipanic medications. |
1998-01-08 |
2023-08-12 |
Not clear |
| D J Quested, P A Sargent, P J Cowe. SSRI treatment decreases prolactin and hyperthermic responses to mCPP. Psychopharmacology. vol 133. issue 3. 1998-01-07. PMID:9361338. |
we studied the effect of 3 weeks treatment with the selective serotonin re-uptake inhibitor (ssri), paroxetine (30 mg daily), on the neuroendocrine and hyperthermic responses to the 5-ht2c receptor agonist, m-chlorophenylpiperazine (mcpp) (0.05 mg/kg i.v. |
1998-01-07 |
2023-08-12 |
human |
| K Muneoka, M Mikuni, T Ogawa, K Kitera, K Kamei, M Takigawa, K Takahash. Prenatal dexamethasone exposure alters brain monoamine metabolism and adrenocortical response in rat offspring. The American journal of physiology. vol 273. issue 5. 1997-12-16. PMID:9374808. |
[3h]paroxetine binding densities were increased in the hypothalamus and m + p-m at 14 wk of life, which corresponded to increased 5-ht contents in both regions. |
1997-12-16 |
2023-08-12 |
rat |
| A L Montejo-González, G Llorca, J A Izquierdo, A Ledesma, M Bousoño, A Calcedo, J L Carrasco, J Ciudad, E Daniel, J De la Gandara, J Derecho, M Franco, M J Gomez, J A Macias, T Martin, V Perez, J M Sanchez, S Sanchez, E Vicen. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. Journal of sex & marital therapy. vol 23. issue 3. 1997-12-02. PMID:9292833. |
the authors analyzed the incidence of sexual dysfunction (sd) with different selective serotonin reuptake inhibitors (ssris; fluoxetine, fluvoxamine, paroxetine, and sertraline) and hence the qualitative and quantitative changes in sd throughout time in a prospective and multicenter study. |
1997-12-02 |
2023-08-12 |
Not clear |
| J P Kelly, A S Wrynn, B E Leonar. The olfactory bulbectomized rat as a model of depression: an update. Pharmacology & therapeutics. vol 74. issue 3. 1997-11-25. PMID:9352586. |
tricyclic antidepressants (amitriptyline, desipramine), atypical agents (mianserin), selective serotonin reuptake inhibitors (paroxetine, sertraline, fluvoxamine), reversible inhibitors of monoamine oxidase a (moclobemide), as well as putative antidepressants such as 5-hydroxytryptamine1a agonists (zalospirone, ipsapirone), noncompetitive n-methyl-d-aspartate antagonists (mk-801) and triazolobenzodiazepines (alprazolam, adinazolam), have demonstrated antidepressant-like activity in this model. |
1997-11-25 |
2023-08-12 |
rat |
| P Tucker, P Adamson, R Miranda, A Scarborough, D Williams, J Groff, H McLea. Paroxetine increases heart rate variability in panic disorder. Journal of clinical psychopharmacology. vol 17. issue 5. 1997-11-21. PMID:9315988. |
in view of paroxetine's increase of heart rate variability, potential benefits of selective serotonin reuptake inhibitors in decreasing cardiac mortality in panic disorder are discussed. |
1997-11-21 |
2023-08-12 |
human |
| C Sánchez, E Meie. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology. vol 129. issue 3. 1997-11-19. PMID:9084057. |
the behavioral profiles of five clinically used selective serotonin reuptake inhibitors (ssris) citalopram, paroxetine, sertraline, fluvoxamine and fluoxetine, have been compared in animal models of antidepressant (mouse forced swim test), anxiolytic (exploration of black and white test box and foot-shock-induced ultrasonic vocalization in the rat) and antiaggressive (isolation-induced aggressive behavior in the mouse) activity. |
1997-11-19 |
2023-08-12 |
mouse |